Needham & Firm LLC reissued their purchase score on shares of KalVista Prescribed drugs (NASDAQ:KALV – Free Report) in a analysis report report printed on Friday, Benzinga stories. They presently have a $32.00 value goal on the specialty pharmaceutical firm’s inventory.
A number of different equities analysts have additionally weighed in on KALV. HC Wainwright reiterated a purchase score and set a $20.00 value goal on shares of KalVista Prescribed drugs in a report on Friday. Cantor Fitzgerald upgraded shares of KalVista Prescribed drugs to a strong-buy score in a report on Monday, August twenty sixth.
Verify Out Our Newest Inventory Report on KALV
KalVista Prescribed drugs Inventory Down 4.1 %
KALV inventory opened at $12.34 on Friday. The agency has a market cap of $520.60 million, a price-to-earnings ratio of -3.63 and a beta of 0.89. KalVista Prescribed drugs has a 12-month low of $7.21 and a 12-month excessive of $16.88. The corporate’s fifty day easy transferring common is $13.17 and its 200 day easy transferring common is $12.40.
KalVista Prescribed drugs (NASDAQ:KALV – Get Free Report) final launched its earnings outcomes on Thursday, September fifth. The specialty pharmaceutical firm reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Analysis analysts anticipate that KalVista Prescribed drugs will publish -3.57 earnings per share for the present 12 months.
Insider Exercise
In different information, CEO Benjamin L. Palleiko offered 14,215 shares of the enterprise’s inventory in a transaction dated Monday, August nineteenth. The shares have been offered at a mean value of $12.01, for a complete transaction of $170,722.15. Following the completion of the sale, the chief government officer now straight owns 242,527 shares of the corporate’s inventory, valued at $2,912,749.27. The transaction was disclosed in a authorized submitting with the SEC, which is out there at this hyperlink. In different information, CEO Benjamin L. Palleiko offered 14,215 shares of the enterprise’s inventory in a transaction dated Monday, August nineteenth. The shares have been offered at a mean value of $12.01, for a complete transaction of $170,722.15. Following the completion of the sale, the chief government officer now straight owns 242,527 shares of the corporate’s inventory, valued at $2,912,749.27. The transaction was disclosed in a authorized submitting with the SEC, which is out there at this hyperlink. Additionally, insider Paul Okay. Audhya offered 2,135 shares of the enterprise’s inventory in a transaction dated Friday, August twenty third. The inventory was offered at a mean value of $12.40, for a complete transaction of $26,474.00. Following the sale, the insider now straight owns 83,745 shares of the corporate’s inventory, valued at $1,038,438. The disclosure for this sale will be discovered right here. During the last 90 days, insiders have offered 23,452 shares of firm inventory price $282,491. Firm insiders personal 12.30% of the corporate’s inventory.
Institutional Traders Weigh In On KalVista Prescribed drugs
Hedge funds and different institutional buyers have not too long ago made modifications to their positions within the enterprise. nVerses Capital LLC purchased a brand new stake in shares of KalVista Prescribed drugs through the second quarter price about $25,000. EntryPoint Capital LLC purchased a brand new stake in KalVista Prescribed drugs within the 1st quarter price about $92,000. China Common Asset Administration Co. Ltd. grew its place in KalVista Prescribed drugs by 101.6% within the 1st quarter. China Common Asset Administration Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical firm’s inventory price $95,000 after buying an extra 4,043 shares within the final quarter. Entropy Applied sciences LP purchased a brand new stake in KalVista Prescribed drugs within the 1st quarter price about $121,000. Lastly, PEAK6 Investments LLC purchased a brand new stake in KalVista Prescribed drugs within the 1st quarter price about $178,000.
KalVista Prescribed drugs Firm Profile
KalVista Prescribed drugs, Inc, a medical stage pharmaceutical firm, engages within the discovery, improvement, and commercialization of small molecule protease inhibitors for illnesses with unmet wants in the US. The corporate’s product portfolio includes small molecule plasma kallikrein inhibitors focusing on hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Additionally
Obtain Information & Rankings for KalVista Prescribed drugs Day by day – Enter your e mail tackle under to obtain a concise each day abstract of the most recent information and analysts’ rankings for KalVista Prescribed drugs and associated corporations with MarketBeat.com’s FREE each day e mail e-newsletter.
